| アブストラクト | BACKGROUND: Adverse event reporting systems are an important source of safety signals for drug use in pregnancy, but their usefulness in the identification of potential drug-drug interactions (DDIs) remains unclear. OBJECTIVE: Our objective was to explore the reliability of signal detection for pharmacokinetic DDIs during pregnancy in adverse event reporting systems, focusing on potential interactions between antipsychotics (APs) or antidepressants (ADs) and drugs modifying cytochrome P450 (CYP450) activity, increasing the occurrence of gestational diabetes mellitus (GDM). METHODS: Reports related to the use of drugs during pregnancy were identified in VigiBase, the World Health Organization (WHO) global database of adverse event reports. Potential interacting drugs were selected based on WHO Drug Standardised Drug Groupings for CYP450 isoenzymes involved in the metabolic pathway of the AP or AD of interest. We conducted statistical interaction analysis using the omega disproportionality measure and including concomitant medication to identify potential DDIs, followed by a case series review for supporting evidence. Evaluation was subjective by author consensus. RESULTS: Of the 30 drug-drug-event combinations considered, statistical signals emerged for escitalopram, citalopram, and sertraline and the simultaneous use of CYP2D6 inhibitors with a higher relative reporting rate of GDM. However, case series review of reports did not support the existence of these DDIs because of uncertainties regarding the actual timing of medication use reported as concomitant. CONCLUSION: Statistical signals of DDIs between ADs and potential interacting drugs during pregnancy were identified but not pursued further after case reviews. Uncertainty around medication use and event timing affected the reliability of the outcomes. These findings highlight the need to validate signals using detailed report data and stress the importance of accurate medication reporting. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2025/9/3 |
|---|
| 投稿者 | Robiyanto, Robiyanto; Barrett, Jim W; Sandberg, Lovisa; Raemaekers, Boukje C; Noren, G Niklas; Schuiling-Veninga, Catharina C M; Hak, Eelko; van Puijenbroek, Eugene P |
|---|
| 組織名 | Department of PharmacoTherapy, -Epidemiology, and -Economics, Groningen Research;Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV,;Groningen, The Netherlands.;Program Studi Farmasi, Fakultas Kedokteran, Universitas Tanjungpura, Pontianak,;Indonesia.;Uppsala Monitoring Centre, Uppsala, Sweden.;Groningen, The Netherlands. e.p.van.puijenbroek@rug.nl.;Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.;e.p.van.puijenbroek@rug.nl. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40898004/ |
|---|
